Sensei biotherapeutics adopts stockholder rights agreement

Boston, march 07, 2023 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced that a special committee of the board of directors adopted a limited duration stockholder rights agreement (the “rights agreement”) to protect stockholder interests and maximize value for all stockholders.
SNSE Ratings Summary
SNSE Quant Ranking